Abstract：
Mogamulizumab, a monoclonal antibody directed against CC chemokine receptor 4, is approved as a second-line treatment of mycosis fungoides and Sézary syndrome. One of the most common side effects is mogamulizumab-associated rash (MAR), which can present in a variety of clinical and histological types. Clinically, it can be difficult to differentiate between MAR and progression of the underlying disease, so histological examination is crucial for clinicopathological correlation. Current data analyses suggest that MAR is more common in patients with Sézary syndrome and is associated with a significantly better response to treatment, making the distinction from disease progression particularly important. The management of MAR depends on its severity, and therapy may need to be paused. This article presents three cases from our clinic and reviews the current literature on MAR. It emphasizes the importance of understanding MAR in the management of patients with cutaneous lymphomas.
摘要：
Mogamulizumab,一种针对CC趋化因子受体4的单克隆抗体，被批准用于治疗真菌病和Sézary综合征。最常见的副作用之一是mogamulizumab相关的皮疹（MAR），可以存在于各种临床和组织学类型中。临床上,很难区分MAR和潜在疾病的进展，因此，组织学检查对于临床病理相关性至关重要。目前的数据分析表明，MAR在Sézary综合征患者中更为常见，并且与对治疗的反应明显更好相关。区分疾病进展尤为重要。MAR的管理取决于其严重程度，治疗可能需要暂停。本文介绍了我们诊所的三例病例，并回顾了有关MAR的最新文献。它强调了了解MAR在皮肤淋巴瘤患者管理中的重要性。
